The BCTRIMS expanded consensus on treatment of multiple sclerosis: II. The evidences for the use of glucocorticoids and immunomodulatory treatments

Multiple sclerosis is an inflammatory disease in which immunological mechanisms play an important role in causing demyelinating lesions in the central nervous system. A number of drugs acting in different stages of these mechanisms have been tested for its treatment. This paper analyses the most imp...

Full description

Saved in:
Bibliographic Details
Published in:Arquivos de neuro-psiquiatria 2002-09, Vol.60 (3-B), p.875-880
Main Authors: Moreira, Marcos Aurélio, Lana-Peixoto, Marco Aurélio, Callegaro, Dagoberto, Haussen, Sérgio Roberto, Gama, Paulo Diniz, Gabbai, Alberto Alain, Rocha, Fernando Coronetti Gomes, Lino, Angelina Maria Martins
Format: Article
Language:Portuguese
Subjects:
Adjuvants, Immunologic - therapeutic use
Evidence-Based Medicine
Glucocorticoids - therapeutic use
Humans
Interferon-beta - therapeutic use
Multiple Sclerosis - drug therapy
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Multiple sclerosis is an inflammatory disease in which immunological mechanisms play an important role in causing demyelinating lesions in the central nervous system. A number of drugs acting in different stages of these mechanisms have been tested for its treatment. This paper analyses the most important clinical trials with glucocorticoids and immunomodulatory treatments, including human immunoglobulin, using the classes of evidences and types of recommendations as have been defined and widely accepted by the international scientific community. It aims to provide sufficient information to support the BCTRIMS Expanded Consensus on Treatment of MS.
ISSN:0004-282X
DOI:10.1590/S0004-282X2002000500036